Contrast-enhanced ultrasound of histologically proven hepatic epithelioid hemangioendothelioma

Yi Dong, Wen-Ping Wang, Vito Cantisani, Mirko D’Onofrio, Andre Ignee, Lorenzo Mulazzani, Adrian Saftoiu, Zeno Spârchez, Ioan Sporea, Christoph F Dietrich

Yi Dong, Wen-Ping Wang, Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai 200032, China

Vito Cantisani, Department of Radiological Sciences, Oncology and Pathology, Policlinico Umberto I, University Sapienza, 00185 Rome, Italy

Mirko D’Onofrio, Department of Radiology, GB Rossi University Hospital, University of Verona, 37121 Verona, Italy

Christoph F Dietrich, Andre Ignee, Medizinische Klinik 2, Caritas-Krankenhaus Bad Mergentheim, 97980 Bad Mergentheim, Germany

Lorenzo Mulazzani, Department of Medical and Surgical Sciences, St. Orsola-Malpighi Hospital, University of Bologna, 40126 Bologna, Italy

Adrian Saftoiu, Department of Gastroenterology, Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy, 200349 Craiova, Romania

Adrian Saftoiu, Department of Endoscopy, Gastrointestinal Unit, Copenhagen University Hospital, DK-2730 Herlev, Denmark

Zeno Spârchez, Department of Gastroenterology, Institute for Gastroenterology and Hepatology, University of Medicine and Pharmacy, “Iuliu Hatieganu” Cluj-Napoca and Institute for Gastroenterology and Hepatology “O. Fodor”, 200349 Craiova, Romania

Ioan Sporea, Department of Gastroenterology and Hepatology, University of Medicine and Pharmacy Victor Babes, 300041 Timisoara, Romania

Author contributions: Dietrich CF is accepting full responsibility for the conduct of the study, he and all others had access to the data, all had control of the decision to publish; Christoph F planned the study; Dietrich CF, Dong Y, D’Onofrio M, and Cantisani V drafted the manuscript; Dietrich CF and Dong Y performed the statistical analysis; each author made a statement that they approved the final draft submitted; all authors conducted the study, collected and/or interpreted data, and critically revised the manuscript for important intellectual content.

Institutional review board statement: This study was a Retrospective Study, Institutional review board statement was applicable to our current study.

Informed consent statement: This study was a Retrospective Study, patients Informed consent statement was applicable to our current study.

Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.

Data sharing statement: Each author gives permission to the graphic designers to alter the visual aspect of figures, tables, or graphs.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Christoph F Dietrich, MD, PhD, MBA, Professor, Chief, Medizinische Klinik 2, Caritas Krankenhaus Bad Mergentheim Uhlandstr 7, D-97980 Bad Mergentheim, Germany. christoph.dietrich@ckbm.de

Telephone: +49-7931-582201
Fax: +49-7931-582290

Received: January 8, 2016
Peer-review started: January 10, 2016
First decision: February 18, 2016
Revised: March 15, 2016
Accepted: April 7, 2016
Article in press: April 7, 2016
Published online: May 21, 2016
Abstract

AIM: To analyze contrast-enhanced ultrasound (CEUS) features of histologically proven hepatic epithelioid hemangioendothelioma (HEHE) in comparison to other multilocular benign focal liver lesions (FLL).

METHODS: Twenty-five patients with histologically proven HEHE and 45 patients with histologically proven multilocular benign FLL were retrospectively reviewed. Four radiologists assessed the CEUS enhancement pattern in consensus.

RESULTS: HEHE manifested as a single (n = 3) or multinodular (n = 22) FLL. On CEUS, HEHE showed rim-like (18/25, 72%) or heterogeneous hyperenhancement (7/25, 28%) in the arterial phase and hypoenhancement (25/25, 100%) in the portal venous and late phases (PVLP), a sign of malignancy. Eighteen patients showed central unenhanced areas (18/25, 72%); in seven patients (7/25, 28%), more lesions were detected in the PVLP. In contrast, all patients with hemangioma and focal nodular hyperplasia showed hyperenhancement as the most distinctive feature (P < 0.01).

CONCLUSION: CEUS allows for characterization of unequivocal FLL. By analyzing the hypoenhancement in the PVLP, CEUS can determine the malignant nature of HEHE.

Key words: Guidelines; Recommendations; Liver tumor; Biopsy; Liver transplantation Contrast enhanced ultrasound

© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In this retrospective study, a large cohort of very rare histologically proven hemangioendothelioma (HEHE) was evaluated. Contrast-enhanced ultrasound (CEUS) allowed for improved detection of multilocular HEHE. HEHE showed typical enhancement patterns on CEUS. Therefore, CEUS can help to determine the malignant nature of HEHE.

Dong Y, Wang WP, Cantisani V, D’Onofrio M, Ignee A, Mulazzani L, Safioiu A, Sparchez Z, Spera I, Dietrich CF. Contrast-enhanced ultrasound of histologically proven hepatic epithelioid hemangioendothelioma. World J Gastroenterol 2016; 22(19): 4741-4749 Available from: URL: http://www.wjgnet.com/1007-9327/full/v22/i19/4741.htm DOI: http://dx.doi.org/10.3748/wjg.v22.i19.4741

INTRODUCTION

Hepatic epithelioid hemangioendothelioma (HEHE) is a rare vascular neoplasm of endothelial origin with primary liver involvement and is characterized by the presence of epithelioid endothelial cells[1]. Weiss and Enzinger first reported 41 patients with this unique tumor in 1982[2]. This tumor is histologically characterized by an epithelial appearance and the endothelial nature of the tumor cells[3]. Currently no more than 200 patients with HEHE have been reported since its first description, and most of the studies were small series[4,5].

No definite etiopathogenetic factors, apart from an association with oral contraceptives, trauma, and exposure to vinyl chloride, have to date been ascribed to HEHE[1,6]. The tumor generally affects adults, with a strong female predominance and a peak incidence occurring between 30 and 40 years of age. The clinical manifestations and laboratory data of HEHE are nonspecific, usually presenting with general symptoms, such as right upper quadrant pain or weight loss. Some patients may present with liver failure, Budd-Chiari syndrome, or portal hypertension, while others may be asymptomatic. Its clinical course and prognosis are variable and unpredictable[7]. Due to its nonspecific clinical manifestations and prolonged clinical course, establishing diagnosis even with histopathological findings can often be challenging[8].

HEHE carries intermediate malignant potential, and transplantation may provide a long term cure[9]. Therefore, the recognition of the imaging features of this rare neoplasm may be helpful for the detection and further surgical treatment of this potentially curable disease. In addition, it is important to distinguish HEHE from other primary and secondary benign and malignant hepatic tumors, such as atypical (multilobulated) hemangioma and hemangiomatosis, hepatocellular adenoma and hepatocellular carcinoma, intrahepatic cholangiocarcinomas, lymphoma, and liver metastases[10]. Radiologists should be aware of its imaging findings and raise suspicion in the proper clinical setting[8,11].

Conventional ultrasound is the most commonly used imaging method for real time diagnosis of FLL. However, the most frequent imaging findings of multilocular HEHE are nonspecific[12]. Often, multiple HEHE on conventional ultrasound might be difficult to differentiate from other atypical multilocular FLLs[12,13]. As a result, the final diagnosis of HEHE depends on biopsy and histological findings[14,15].

Contrast enhanced ultrasound (CEUS) allows for the differentiation of most benign and malignant liver tumors in the portal venous and late phases (PVLP). This finding was summarized in the European Federation of Societies for Ultrasound in Medicine and Biology guidelines and recommendations for the use of CEUS in liver[16,17]. Benign FLs are typically iso- or hyperenhancing in the PVLP; whereas malignant primary and secondary liver tumors almost always show hypoenhancement in the PVLP, since they do not contain the respective specific hepatic vessels. This hypoenhancement in the PVLP is decisive for determining if a lesion should be biopsied[18,19]. In
addition, CEUS findings of HEHE have not been well addressed. Therefore, the aim of our study is to analyze the CEUS features of histologically proven HEHE and to compare these features to those of other multilocular benign FLLs, including hemangiomas and focal nodular hyperplasia (FNH), since they are the most important for differential diagnosis. We assessed the clinical value of CEUS to define the malignant nature of the disease with hypoenhancement in the PVLP. To our best knowledge, this is the first report on the CEUS features of HEHE.

MATERIALS AND METHODS

Patients
Hemangioendothelioma: Between September 2004 and October 2015, 25 patients (eight male, 17 female, mean age 46 ± 14 years; range 24-78 years) were retrospectively analyzed. In this retrospective study, lesions were histologically proven by hepatic surgery (n = 6) or by 18-gauge core needle biopsy (n = 19).

Three patients had a single FLL, whereas 22 patients had multiple FLLs (Table 1). In patients with multiple FLLs, the selected lesions were those in which biopsies had been performed.

Table 1 Baseline characteristics of patients included in our study

| Characteristic                  | HEHE (n = 25) | Hemangioma and FNH (n = 45) |
|--------------------------------|---------------|----------------------------|
| Age (yr)                       | 46 ± 14       | 46 ± 14                    |
| Range                          | 24-78         | 23-74                      |
| Male/female                    | 8/17          | 9/36                       |
| Number of FLL (single/multiple)| 3/22          | 0/45                       |
| Histological results           |               |                            |
| hepatic surgery                | 6             | 0                          |
| core needle biopsy              | 19            | 45                         |

HEHE: Hepatic epithelioid haemangioendothelioma; FNH: Focal nodular hyperplasia; FLL: Focal liver lesions.

Multilocular hemangioma and FNH
Forty-five patients (nine male, 36 female, mean age 46 ± 14 years; range 24-78 years) with multilocular hemangioma and FNH were also retrospectively analyzed. All lesions were histologically proven by 18-gauge core needle biopsy.

Examination technique
Conventional ultrasound and CEUS were performed by five ultrasound systems: LOGIQ E9 (GE Healthcare, Milwaukee, WI, United States; C1-5 convex array probes, 1-5MHz), Acuson Sequoia (Siemens Healthcare, Erlangen, Germany, 3.5 MHz), Philips IU22 unit (Philips Healthcare, Bothell, WA, United States; CS-1 convex array probes, 1-5MHz), Technos MPX Scanner, and MyLab70 (Esaote, Genova, Italy; ca431 convex array probe 1-8 MHz).

CEUS was performed using contrast harmonic real time imaging at a low MI 0.05-0.30. Each examination lasted about 5 min after the bolus injection. The contrast agent used was SonoVue® (Bracco Imaging Spa, Milan, Italy). For each CEUS examination, a dose of 1.5-2.4 mL of SonoVue® was injected as a quick bolus via a 20 gauge intravenous catheter placed in the cubital vein, followed by 5-10 mL of 0.9% normal saline flush. Repeated injection of SonoVue® was performed when necessary.

To characterize the lesion, SonoVue® enhancement during the arterial phase (10-30 s), portal venous (20-120 s), and late vascular phases (120-300 s) were evaluated[17]. All examinations were digitally recorded.

Image analysis
All HEHE images were read by four independent radiologists (15, 17, 23, and 27 years of experience with abdominal ultrasound imaging) blinded to clinical and pathologic data in consensus. Criteria evaluated included number of lesions, maximum diameter, echogenicity (hyperechoic, hypoechoic, or isoechoic; homogeneous or heterogeneous; which were visually compared with the echogenicity of the surrounding liver parenchyma), shape (regular or lobulated), margin (ill- or well defined appearance), and color Doppler imaging features. Using CEUS, the pattern of contrast enhancement of the lesion in comparison to the surrounding liver parenchyma (hypoenhancing, hyperenhancing, isoenhancing), homogeneity of enhancement (homogeneous, heterogeneous), and additional features of enhancement during the arterial, portal venous, and late phases were noted as well, e.g., rim-like or peripheral nodular enhancement, central or eccentric arterial enhancement.

CEUS features of 45 patients of histologically proven multilocular liver hemangioma and FNH were also retrospectively evaluated to compare the CEUS features for differential diagnosis. Digital cine loops were registered both during baseline and post contrast US scanning. All cine loops were digitally stored in a PC based workstation connected to the ultrasound systems.

Pathologic examination
The final pathologic diagnosis was based on hematoxylin-eosin stained sections and immunohistochemical staining results. The immunohistochemical staining included endothelial markers, such as CD 34, CD 31, and factor VIII-related antigen (FVIII Ag)[20].

Statistical analysis
Data are expressed as mean ± SD. All statistical analyses were performed with SPSS 17.0 software package (SPSS, Chicago, IL, United States). The χ² test was used to compare HEHE with liver hemangiomas and FNH in terms of enhancement pattern. For the features that played a statistically significant role in
FLL was observed (2/25, 8%). Color Doppler imaging detected branched intra-lesional vessels in 84% (21/25) of HEHE. The Doppler spectrum was measured in 13 patients. The mean value of resistive index (RI) was 0.64 ± 0.07 (Figure 1 and Table 2).

**CEUS features**

On CEUS, HEHE presented peripheral rim-like (18/25, 72%) (Figure 2) or heterogeneous hyperenhancement (7/25, 28%) at the arterial phase (Figure 3) and hypoenhancement (100%, 25/25) at PVLP (Figure 4). Central unenhanced areas were observed in 72% (18/25) of HEHE in the late phases. After CEUS, more lesions could be detected in seven patients of HEHE than with conventional ultrasound. Liver hemangioma typically demonstrated peripheral nodular contrast enhancement in all patients, whereas FNH showed central or eccentric arterial blood supply in the arterial phase. In addition, in all patients, both entities showed hyperenhancement in the PVLP, a sign of the benign nature of the lesion. Compared to multilocular liver hemangioma and FNH, characteristic CEUS features of HEHE were peripheral rim-like hyperenhancement in the arterial phase and quick washout in the PVLP with a central unenhanced area in the late phase (P < 0.01) (Table 3).

The sensitivity for peripheral rim-like hyperenhancement at the arterial phase was 72%; for differentiation diagnosis, we calculated sensitivity and specificity. A difference was considered statistically significant with P < 0.05.

**RESULTS**

**Clinical and general pathologic features**

All patients were incidentally found to have hepatic lesions by conventional ultrasound screening. Conventional laboratory tests [including transaminases, bilirubin, and gamma-glutamyl transpeptidase (gGT)] were within normal limits or only slightly elevated in all patients. Alpha-fetoprotein, carcinoembryonic antigen, and cancer antigen 19-9 as well as hepatitis B surface antigen and hepatitis C virus were negative respective of normal in all patients.

Final pathologic diagnosis of HEHE showed the typical fibrosclerotic center and cellular periphery on hematoxylin-eosin staining. Immunohistochemically, tumors were positive for at least one endothelial marker, including CD 34 (n = 20), CD 31 (n = 20), or FVIII Ag (n = 11).

**Features with conventional ultrasound in HEHE**

HEHE manifested as single (3/25, 12%) or multiple FLLs (22/25, 88%) with ill-defined margins on grayscale ultrasound. The lesions were mainly hypoechoic (23/25, 92%) to adjacent liver parenchyma, but a heterogeneous echogenicity with hypo- or hyperechoic FLL was observed (2/25, 8%). Color Doppler imaging detected branched intra-lesional vessels in 84% (21/25) of HEHE. The Doppler spectrum was measured in 13 patients. The mean value of resistive index (RI) was 0.64 ± 0.07 (Figure 1 and Table 2).
quick washout in the PVLP, it was 100%; for central unenhanced area at late phase, it was 72%; and for the combination of both, it was 85% (Table 3).

**DISCUSSION**

To the best of our knowledge, CEUS features of HEHE have not been well characterized. To date, only a few imaging studies have investigated HEHE, and most of them were limited patients series\(^4,15,21\), and CEUS features of HEHE have been described only in a few patients\(^{15,21,22}\). In many patients, CEUS is the first and decisive imaging technique for detecting and characterizing liver tumors\(^{23-25}\). The use of ultrasound contrast agents improved detection and made it possible to assess the benign or malignant nature of liver tumors in most patients\(^{13,26-28}\). Previously, three forms of HEHE have been described: single nodular, multifocal nodular, and the diffuse type\(^1\). Consistent with our current study, most HEHE present as multiple FLL. After CEUS, more lesions could be detected in 7/25 (28%) patients\(^{29}\). As HEHE has ill-defined margins on grayscale ultrasound, CEUS may be helpful to detect more lesions with sharper and clearer margins.

In our current retrospective study, we discovered that CEUS reliably showed typical signs of HEHE in most patients with hyperenhancement in the arterial phase and hypoenhancement in the PVLP, which might be useful in determining whether a biopsy is necessary for suspected malignant lesions. In correlation with pathologic classification, histologically, HEHE possesses two distinctive characteristics, which are directly related to the echogenicity and enhancement pattern of HEHE on ultrasound images\(^1,20,30,31\). First, HEHE are composed of dendritic and epithelioid cells with intracytoplasmic lumina containing red blood cells. However, the peripheral proliferation remains active and forms numerous arterial-venous shunts, which

| Characteristic                              | HEHE (n = 25) | Hemangioma/FNH (n = 45) |
|---------------------------------------------|---------------|------------------------|
| Number of nodules (single/multiple)         | 3/22          | 0/45                   |
| Size of nodules (mm)                        |               |                        |
| mean ± SD                                   | 41.5 ± 25.6   | 50.4 ± 25.7            |
| range                                       | 12-120        | 20-138                 |
| Echogenicity of nodules                     |               |                        |
| Hyperechoic                                 | 2 (8)         | 19 (42.2)              |
| Hypoechoic                                  | 23 (92)       | 9 (20.0)               |
| Isoechoic                                   | 0             | 17 (37.8)              |
| Homogenous/heterogeneous                    | 9/16          | 15/30                  |

HEHE: Hepatic epithelioid haemangioendothelioma; FNH: Focal nodular hyperplasia.

---

**Figure 2** Contrast-enhanced ultrasound feature of hepatic epithelioid hemangioendothelioma in a 31 year female. A: Rim-like enhancement. In arterial phase (16 s after injection of SonoVue), peripheral rim-like enhancement was demonstrated; B: In peak enhancement (24 s after injection of SonoVue), the degree of the rim-like enhancement was equivalent to the liver parenchyma; C: In portal venous phase (45 s after injection of SonoVue), the lesion washed out quickly and showed hypoenhancement; D: In late phase (65 s after injection of SonoVue), the lesion remained hypoenhanced with central unenhanced area.
Figure 3  Contrast-enhanced ultrasound feature of hepatic epithelioid hemangioendothelioma in a 25 year female. A: Heterogeneous enhancement pattern. In the arterial phase (16 s after injection of SonoVue), the lesion showed heterogeneous enhancement; B: The enhancement gradually decreased (22 s after injection of SonoVue); C: In the portal venous phase (40 s after injection of SonoVue), the lesion washed out fast than the liver parenchyma and showed hypoenhancement. D: In the late phase (165 s after injection of SonoVue), the lesion remained hypoenhanced.

Figure 4  Contrast-enhanced ultrasound feature of hepatic epithelioid hemangioendothelioma in right lobe of liver. A: Grayscale ultrasound showed a hypoechoic focal liver lesions (FLL); B: In the arterial phase the lesion showed heterogeneous enhancement (22 s after injection of SonoVue); C: In the portal venous phase (53 s after injection of SonoVue), the lesion washed out fast and showed hypoenhancement.
Table 3  Contrast enhanced ultrasound imaging features of hepatic epithelioid haemangiendothelioma and multilocular hemangioma/ focal nodular hyperplasia $\eta$ (%)

| Characteristic                     | HEHE $\eta = 25$ patients | Hemangioma/FNH $\eta = 45$ patients |
|------------------------------------|---------------------------|--------------------------------------|
| Arterial phase                     |                           |                                      |
| Rim like hyperenhancement          | 18/25 (72)                | 0                                    |
| Heterogeneously                    | 7 (28)                    | 0                                    |
| Hyperenhancement                   | 6 (13.3)                  |                                      |
| Peripheral nodular enhancement    | 0                         | All hemangioma                       |
| Central arterial blood supply      | All FNH                   |                                      |
| Portal-venous phase                |                           |                                      |
| Hyperenhancement                   | 0                         | 100 (100.0%)                         |
| Hypoenhancement                    | 25 (100)                  | 0                                    |
| Isoenhancement                     | 0                         | 0                                    |
| Late phase                         |                           |                                      |
| Hyperenhancement                   | 0                         | 45 (100.0%)                          |
| Hypoenhancement                    | 25 (100)                  | 0                                    |
| Isoenhancement                     | 0                         | 0                                    |
| Sensitivity                        |                           |                                      |
| Rim like hyperenhancement          | 18/25 (72)                | 0                                    |
| Hypoenhancement at portal venous phase | 25/25 (100)              | 0                                    |
| Central unenhanced area at late phase |                         |                                       |
| Yes                                | 18/25 (72)                | 13 (28.9)                            |
| No                                 | 7 (28)                    | 32 (71.1)                            |

CEUS: Contrast enhanced ultrasound; HEHE: Hepatic epithelioid haemangiendothelioma; FNH: Focal nodular hyperplasia.

could account for the fast rim-like enhancement in the arterial phase and quick washout in the PVLP during CEUS\cite{7}. Second, tumor cells and stroma of HEHE exist in variable proportions, and the central stromal portion of the lesion can vary from myxoid to densely fibrotic. With the growth of the tumor, the central stroma degenerate gradually and become sclerotic as the blood supply decreases\cite{20}. In our results, hypoenhancement with central unenhanced area at PVLP of CEUS was mostly common in HEHE. Moreover, additional lesions were detected at CEUS, leading to improvements in liver staging.

Alomari et al\cite{33} first described the lollipop sign as a new cross-sectional sign of HEHE on computed tomography (CT) and magnetic resonance imaging (MRI): a well-defined peripherally enhancing (or non-enhancing) lesion with an avascular core on enhanced images (the candy in the lollipop) and a histologically occluded vein (the stick). Concerning the CT imaging, focal calcifications were reported in 20% of patients; capsular retraction was in 10%-25% of patients\cite{20}. The lesions demonstrated peripheral rim-like hyperenhancement in the arterial phase with even stronger enhancement in the portal venous phase by contrast enhanced MRI. Central areas of reduced signal may correspond to areas of hemorrhage, coagulation necrosis, and calcification\cite{7}. We showed that peripheral rim-like hyperenhancement in the arterial phase and hypoenhancement in the PVLP with central unenhanced areas could be detected in 72% HEHE patients. Therefore, the contrast enhanced image modalities demonstrate a similar enhancement pattern of this disease. CEUS can be considered at least equal to, and in some ways (real time observation, no radiation, less expensive) superior to, CT and MRI as a diagnostic tool\cite{33}.

Most of the HEHE lesions were multinodular (88%) and hypoechic (92%) in our current study. As set out in the current literature and in textbooks, the origin of hypoechic lesions is considerably more varied and confusing than other lesions\cite{13,23}. All hypoechogenic lesions should be investigated using a contrast enhanced imaging technique\cite{16,18}. Evaluation with CEUS in the PVLP is determinant in this context, and contrast medium hypoenhancement in the late phase is a decisive indication for liver biopsy\cite{23}.

HEHE has a variable clinical and biological course compared to benign endothelial tumors (hemangiomas) and malignant angiosarcomas with a slowly progressive phenotype. The tumor can even be difficult to diagnose based on biopsy specimens\cite{34}. CEUS differentiation of different liver tumors is essential because of different therapeutic approaches\cite{35}. HEHE should be differentiated from atypical multilocular liver hemangioma and FNH, because both of them could demonstrate as multilocular hypoechic liver lesions. Although benign FLLs are commonly iso- or hypoenhancing in the PVLP, malignant primary and secondary liver tumors almost always show hypoenhancement in the PVLP\cite{18,19}. Based on results of our retrospective analysis, we believe that peripheral rim-like hyperenhancement at the arterial phase and quick washout at the PVLP with central unenhanced area are hallmark features that suggest a diagnosis of possible HEHE. In contrast, both multilocular hemangiomas and FNH showed hypoenhancement and remained iso or hyperehanced in PVLP.

Furthermore, in the clinical setting, factors helpful for the differential diagnosis of HEHE are a medical history without extrahepatic malignant tumor, patients with no symptoms, and laboratory tests\cite{35}.

In conclusion, CEUS imaging findings reliably compile typical signs of HEHE, allowing for effective differentiation with other multilocular hypoechic hepatic lesions, including liver hemangioma and FNH. CEUS can help to improve the diagnostic confidence of HEHE, a rare hepatic tumor, and the liver staging of the disease to guide additional diagnostic work-up.

COMMENTS

Background

To our best knowledge, contrast-enhanced ultrasound (CEUS) features of hepatic epithelioid hemangiendothelioma (HEHE), a rare hepatic tumor, have not been well characterized. To date, only a few imaging studies have investigated HEHE, and most of them were limited patients series.

Research frontiers

This is the first report on the CEUS features of HEHE.
Innovations and breakthroughs

CEUS imaging findings reliably compile typical signs of HEHE and differentiate effectively it from other multicellular hypoochastic hepatic lesions, including liver hemangioe and focal nodular hyperplasia.

Applications

CEUS can help to improve the diagnostic confidence and liver staging of HEHE to guide additional diagnostic work-up.

Terminology

CEUS allows for the differentiation of most benign and malignant liver tumors in the portal venous and late phases.

Peer-review

The aim of this retrospective study was to analyze the CEUS features of histologically proven HEHE in comparison to other multicellular benign focal liver lesions, which might be important differential diagnosis, and to assess the clinical value of CEUS to define the malignant nature of HEHE with hypeoenhancement in the portal-venous and late phase.

REFERENCES

1. Makkolof HR, Ishak KG, Goodman ZD. Epithelioid hemangioendothelioma of the liver: a clinicopathologic study of 137 cases. Cancer 1999; 85:562-582 [PMID: 10991730 DOI: 10.1002/ (SICI)1097-0142(19990201)85:2<562::AID-CNCR2>3.0.CO;2-J]

2. Weiss SW, Enzinger FM. Epithelioid hemangioendothelioma: a vascular tumor often mistaken for a carcinoma. Cancer 1982; 50:970-981 [PMID: 709331 DOI: 10.1002/1097-0142(19820901)50:3<970::AID-CNCR2>3.0.CO;2-5]

3. Furui S, Itai Y, Ohtomo K, Yamauchi T, Takenaka E, Iio M, IbuKuro Y, Ishii Y, Inoue Y. Hepatic epithelioid hemangioendothelioma: report of five cases. Radiology 1989; 171:63-68 [PMID: 2648478 DOI: 10.1148/radiology.171.1.2648478]

4. Chen Y, Yu RS, Qiu LL, Jiang DY, Tan YB, Fu YB. Contrast-enhanced multiple-phase imaging features in hepatic epithelioid hemangioendothelioma. World J Gastroenterol 2011; 17:3544-3553 [PMID: 21941423 DOI: 10.3748/wjg.v17.i30.3544]

5. Casadei Gardini A, Pieri F, Fusaroli P, Oboldi D, Passardi A, Monti M, Rosetti P, Calpona S, Valgiusti M, Lambilliotte JP. Epithelioid hemangioendothelioma of the liver: follow-up contact with vinyl chloride. Recurrence after orthotopic liver transplantation. J Hepatol 1989; 8:99-106 [PMID: 2646369 DOI: 10.1016/1688-8278(89)90183-2]

6. Amin S, Chung H, Jia R. Hemangioid hemangioendothelioma: MR imaging findings. Abdom Imaging 2011; 36:407-414 [PMID: 21079951 DOI: 10.1007/s00261-010-0662-0]

7. Mehrabi A, Kashfi A, Fonouni H, Schmied BM, Hallseidt P, Schirmacher P, Weitz J, Friess H, Buchler MW, Schmidt J. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer 2006; 107:2108-2121 [PMID: 17019735 DOI: 10.1002/cncr.22225]

8. Agrawal N, Parajuli S, Zhao P, Sakkar R, Laurin J, Azumi N, Matsamoto C, Shtey K. Liver transplantation in the management of hepatic epithelioid hemangioendothelioma: a single-center experience and review of the literature. Transplant Proc 2011; 43:2647-2650 [PMID: 21911139 DOI: 10.1016/j.transproceed.2011.06.035]

9. Orlando G, Adam R, Mirza D, Sodderghal G, Porte RJ, Paul A, Burroughs AK, Seiler CA, Colladan M, Graziaidi I, Garcia Valdecasas JC, Pruvot FR, Karam V, Lerut J. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation—the European Liver Transplant Registry experience. Transplantation 2013; 95:872-877 [PMID: 23354302 DOI: 10.1097/TP.0b013e318281b902]

10. Perera B, Osbyte T. Prevalence and correlates of sexual abuse reported by late adolescent school children in Sri Lanka. Int J Adolesc Med Health 2009; 21:203-211 [PMID: 19702200 DOI: 10.1111/j.1445-5994.2009.00433.x]

11. Fröhlicher E, Jenssen C, Schuler A, Dietrich CF. [Contrast-enhanced ultrasound for characterisation of focal liver lesions, practical advice]. Z Gastroenterol 2015; 53:1099-1107 [PMID: 26367027 DOI: 10.1055/s-0035-1533491]

12. Dietrich CF, Cui XW, Boozari B, Hocke M, Ignee A. Contrast-enhanced ultrasound (CEUS) in the diagnostic algorithm of hepatocellular and cholangiocellular carcinoma, comments on the AASLD guidelines. Ultraschall Med 2012; 33 Suppl 1: S57-S66 DOI: 10.1055/s-0032-1312903

13. Azzam RI, Alshak NS, Pham HP. AIRP best cases in radiologic-pathologic correlation: Hepatic epithelioid hemangioendothelioma. Radiographics 2012; 32:789-794 [PMID: 22582359 DOI: 10.1148/rg.321115010]

14. Cui XW, Ignee A, Woenckhaus M, Dietrich CF. Hemangiogendothelioma, an Imaging Challenge. Endheu 2014; 37:34-36 [DOI: 10.1055/s-0034-1366060]

15. Claunder M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolaeo CP, Piscaglia F, Wilson SR, Barr RG, Channas MC, Chaubal NG, Chen MH, Clevert DA, Correaes JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leon EL, Matrey RF, Moriyasu F, Solbiati L, Westhoff PK, Xu XY. Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) in the liver -update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasschall Med 2013; 34:11-29 [PMID: 23129518 DOI: 10.1055/s-0032-125499]

16. Claunder M, Dietrich CF, Choi BI, Cosgrove DO, Kudo M, Nolaeo CP, Piscaglia F, Wilson SR, Barr RG, Channas MC, Chaubal NG, Chen MH, Clevert DA, Correaes JM, Ding H, Forsberg F, Fowlkes JB, Gibson RN, Goldberg BB, Lassau N, Leon EL, Matrey RF, Moriyasu F, Solbiati L, Westhoff PK, Xu HY. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS. Ultrasschall Med Biol 2013; 39:187-210 [PMID: 23137926 DOI: 10.1016/j.ultrasmedbio]

17. Strobel D, Seitz K, Blank W, Schuler A, Dietrich CF, von Herbay A, Friedrich-Rust M, Bernatik T. Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioe and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS). Ultrasschall Med 2009; 30:376-382 [PMID: 19688669 DOI: 10.1055/s-0028-1109672]

18. Bernatik T, Seitz K, Blank W, Schuler A, Dietrich CF, Strobel D. Unclear focal liver lesions in contrast-enhanced ultrasonography-lessons to be learned from the DEGUM multicenter study for the characterization of liver tumors. Ultraschall Med 2010; 31:577-581 [PMID: 20740399 DOI: 10.1055/s-0030-1245649]

19. Lin J, Ji Y. CT and MRI diagnosis of hepatic epithelioid hemangioendothelioma. Hepatobiliary Pancreat Dis Int 2010; 9:154-158 [PMID: 20382594]

20. Bourns K, Vanhoenacker PF, Roskams T, DHaenens P, Van Hoe L. Epithelioid hemangioendothelioma of the liver: radiologic-pathologic correlation. Abdom Imaging 2004; 29: 221-223 [PMID: 15290949 DOI: 10.1007/s00261-003-0094-y]

21. Schweitzer N, Soudah B, Gebel M, Manne MP, Boozari B. Gray scale and contrast-enhanced ultrasound imaging of malignant liver tumors of vascular origin. United European Gastroenterol J 2015; 3:63-71 [PMID: 25653860 DOI: 10.1177/2050604614560604]

22. Dietrich CF, Sharma M, Gibson RN, Schreiber-Dietrich D, Jenssen C. Fortuitously discovered liver lesions. World J Gastroenterol 2013; 19:3173-3188 [PMID: 23745019 DOI: 10.3748/wjg.v19.i21.3173]

23. Dietrich CF. Liver tumor characterization--comments and illustrations regarding guidelines. Ultrasschall Med 2012; 33 Suppl
Dong Y et al. CEUS of HEHE

1: S22-S30 [PMID: 22723025 DOI: 10.1055/s-0032-1312892]

25 Dietrich CF, Cui XW, Schreiber-Dietrich DG, Ignee A. EFSUMB guidelines 2011: comments and illustrations. Ultraschall Med 2012; 33 Suppl 1: S11-S21 [PMID: 22723024]

26 Dietrich CF, Ignee A, Trojan J, Fellbaum C, Schuessler G. Improved characterisation of histologically proven liver tumours by contrast enhanced ultrasonography during the portal venous and specific late phase of SHU 508A. Gut 2004; 53: 401-405 [PMID: 14960524 DOI: 10.1136/gut.2003.026260]

27 Dietrich CF, Cui XW, Barreiros AP, Hocke M, Ignee A. EFSUMB guidelines 2011: comment on emergent indications and visions. Ultraschall Med 2012; 33 Suppl 1: S39-S47 [PMID: 22723028 DOI: 10.1055/s-0032-1312895]

28 Seitz K, Strobel D, Bernatik T, Blank W, Friedrich-Rust M, Herbay Av, Dietrich CF, Strunk H, Kratzer W, Schuler A. Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions - prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreiländertreffen 2008, Davos. Ultraschall Med 2009; 30: 383-389 [PMID: 19688670 DOI: 10.1055/s-0028-1109673]

29 Dietrich CF, Kratzer W, Strobe D, Danse E, Fessl R, Bunk A, Vossas U, Hauenstein K, Koch W, Blank W, Oudkerk M, Hahn D, Greis C. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J Gastroenterol 2006; 12: 1699-1705 [PMID: 16586537 DOI: 10.3748/wjg.v12.i11.1699]

30 Kim EH, Rha SE, Lee YJ, Yoo IeK, Jung ES, Byun JY. CT and MR imaging findings of hepatic epithelioid hemangioendotheliomas: emphasis on single nodular type. Abdom Imaging 2015; 40: 500-509 [PMID: 25179888 DOI: 10.1007/s00261-014-2293-3]

31 Miller WJ, Dodd GD, Federle MP, Baron RL. Epithelioid hemangioendothelioma of the liver: imaging findings with pathologic correlation. AJR Am J Roentgenol 1992; 159: 53-57 [PMID: 1302463 DOI: 10.2214/ajr.159.1.1302463]

32 Alomari AI. The lollipop sign: a new cross-sectional sign of hepatic epithelioid hemangioendothelioma. Eur J Radiol 2006; 59: 460-464 [PMID: 16644166 DOI: 10.1016/j.ejrad.2006.03.022]

33 Chiorean L, Cantisani V, Janssen C, Sidhu PS, Baum U, Dietrich CF. Focal masses in a non-cirrhotic liver: The additional benefit of CEUS over baseline imaging. Eur J Radiol 2015; 84: 1636-1643 [PMID: 26049958 DOI: 10.1016/j.ejrad.2015.05.007]

34 Liu YI, Brown SS, Eihu A, Bonham CA, Concepcion W, Longacre TA, Kamaya A. Hepatic epithelioid hemangioendothelioma. Dig Dis Sci 2011; 56: 303-306 [PMID: 21053076 DOI: 10.1007/s10620-010-1470-4]

35 Dietrich CF, Mertens JC, Braden B, Schuessler G, Ott M, Ignee A. Contrast-enhanced ultrasound of histologically proven liver hemangiomas. Hepatology 2007; 45: 1139-1145 [PMID: 17464990 DOI: 10.1002/hep.21615]

P- Reviewer: Balaban YH, Kaya M, Zhang XC S- Editor: Qi Y L- Editor: Filipodia E- Editor: Zhang DN
